5

10

15

20

a

What is claimed is:

- 1. A method for modulating metabolism of pathogenic Mycoplasma bacteria comprising the step of contacting pathogenic Mycoplasma bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or antibacterially effective derivatives thereof.
- 2. The method of claim 1 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of

Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.

- 3. A method of treating or preventing a bacterial infection by pathogenic Mycoplasma bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound to a mammal suspected of having or being at risk of having an infection with pathogenic Mycoplasma bacteria.
- 4. The method of claim 3 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:

Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.

- 5. The method of claim therein said modulating metabolism is inhibiting growth of said bacteria.
- 6. The method of claim 1 wherein said modulating metabolism is killing said bacteria.
- 7. The method of claim 1 wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal.
 - 3. The method of claim 3 wherein said mammal is a human.
- 25 9. The method of claim 7 wherein said mammal is a human.
 - 10. The method of claim 1 wherein said bacteria is selected from the group consisting of: Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma ureally foum.
- 11. The method of class wherein said bacteria is selected from the group consisting of: Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma grealyticum.

afa

7